PA
CRNC icon

PharVision Advisers’s Cerence CRNC Stock Holding History

PharVision Advisers’s Portfolio CRNC Stock Details CRNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,186
Closed -$194K – 232
2025
Q4 		$194K Buy
+18,186
New +$200K 0.1% 568
2025
Q2 		– Sell
-17,109
Closed -$135K – 298
2025
Q1 		$135K Buy
+17,109
New +$211K 0.19% 232

Other funds holding CRNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
American Capital Management New York $2.23B AUM 28.03% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NSGL
No Street GP LP San Francisco, California $1.66B AUM 39.91% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $310M AUM 45.19% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

PharVision Advisers's CRNC Position: Q1 2026 in Review

PharVision Advisers sold out of Cerence (CRNC) in Q1 2026, closing a stake of 18,186 shares — an estimated $194K sold.

PharVision Advisers first reported a position in CRNC in Q1 2025 and held it in 2 quarters. The position peaked at $194K in Q4 2025. 195 funds tracked by Wall St. Rank hold CRNC as of Q1 2026.

  • PharVision Advisers reported no remaining Cerence position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 18,186 Cerence shares in Q1 2026, an estimated $194K.
  • PharVision Advisers first reported a position in Cerence in Q1 2025 and held it in 2 quarters.
  • PharVision Advisers's Cerence position peaked at $194K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Cerence as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.